Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
ASH Highlights
Meeting Highlights
ASH Highlights
Minimal Residual Disease After Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Read More
Meeting Highlights
ASH Highlights
Isatuximab + Pomalidomide and Dexamethasone in Frail Patients with RRMM: ICARIA-MM Subgroup Analysis
Read More
Meeting Highlights
ASH Highlights
FORTE Trial: Analysis of Survival in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
Read More
Meeting Highlights
ASH Highlights
CARTITUDE-1: Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM
Read More
Meeting Highlights
ASH Highlights
Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy, in Patients with RRMM: CRB-401 Study Updates
Read More
Meeting Highlights
ASH Highlights
Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib
Read More
Meeting Highlights
ASH Highlights
Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study
Read More
Meeting Highlights
ASH Highlights
Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma
Read More
Meeting Highlights
ASH Highlights
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study
Read More
Meeting Highlights
ASH Highlights
ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Read More
1
2
3
4
5
6
7
Page 4 of 7
Results 31 - 40 of 70